Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 2Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × monalizumab × Clear all
NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

MedImmune LLC

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡